FRANKFURT, Feb 3 (Reuters) – Britain’s GlaxoSmithKline and German biotech firm CureVac struck a deal to develop next-generation vaccines against COVID-19 that target several variants in one product.
In a joint statement on Wednesday, the partners said they were targeting a possible launch in 2022.
{iframe}https://www.reuters.com/article/health-coronavirus-gsk-idUSL8N2K91JZ{/iframe}